日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Baculovirus-Mediated Gene Therapy: Targeting BIRC6 for Lung and Breast Cancer

杆状病毒介导的基因治疗:靶向BIRC6治疗肺癌和乳腺癌

Marchesini, Abril; Gómez Bergna, Santiago M; Amorós Morales, Leslie C; López, María Florencia; Vásquez, Larisa; Tongiani, Silvana E; González Morán, Florencia; Romanowski, Víctor; Gottardo, María Florencia; Pidre, Matias L

PluriBAC: A Versatile Baculovirus-Based Modular System to Express Heterologous Genes in Different Biotechnological Platforms

PluriBAC:一种多功能的基于杆状病毒的模块化系统,可在不同的生物技术平台上表达异源基因

Amorós Morales, Leslie C; Marchesini, Abril; Gómez Bergna, Santiago M; García Fallit, Matías; Tongiani, Silvana E; Vásquez, Larisa; Ferrelli, María Leticia; Videla-Richardson, Guillermo A; Candolfi, Marianela; Romanowski, Víctor; Pidre, Matías L

Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors

新型双重细菌 DNA 型 II 拓扑异构酶抑制剂的抗菌活性

Noemi D'Atanasio, Alessandra Capezzone de Joannon, Laura Di Sante, Giorgina Mangano, Rosella Ombrato, Marco Vitiello, Cristina Bartella, Gabriele Magarò, Federica Prati, Claudio Milanese, Carla Vignaroli, Francesco Paolo Di Giorgio, Serena Tongiani

Management and Treatment of Patients With Major Depressive Disorder and Chronic Diseases: A Multidisciplinary Approach

重度抑郁症合并慢性疾病患者的管理和治疗:多学科协作模式

Almeida, Susana Sousa; Zizzi, Francesca Benedetta; Cattaneo, Agnese; Comandini, Alessandro; Di Dato, Giorgio; Lubrano, Ennio; Pellicano, Clelia; Spallone, Vincenza; Tongiani, Serena; Torta, Riccardo

New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment

普鲁利沙星治疗轻度、中度和重度肾功能不全患者后乌利沙星药代动力学的新见解

Tellone, Valeria; Coppola, Paola; Ammendola, Marco; Di Loreto, Giorgio; Picollo, Rossella; Del Vecchio, Alessandra; Comandini, Alessandro; Garofolo, Fabio; Tongiani, Serena

Tetanus toxin L chain is processed by major histocompatibility complex class I and class II pathways and recognized by CD8+ or CD4+ T lymphocytes

破伤风毒素 L 链由主要组织相容性复合体 I 类和 II 类途径处理,并被 CD8+ 或 CD4+ T 淋巴细胞识别

I Kerblat, S Tongiani-Dahshan, C Aude-Garcia, M Villiers, C Drouet, P N Marche